Abeta toxicity 1 [electronic resource] / Colin L. Masters.
Material type:
FilmSeries: Henry Stewart talksBiomedical & life sciences collection. Alzheimer's disease: ; Henry Stewart talksBiomedical & life sciences collection. Drug discovery and development in the neurosciences: Publisher: London : Henry Stewart Talks, 2011Description: 1 online resource (1 streaming video file (54 min.) : color, sound)Other title: Title from title frames: Aβ toxicity, Part I | Abeta toxicity, Part ISubject(s): Alzheimer's disease -- Chemotherapy | Alzheimer's disease -- Pathophysiology | Alzheimer's disease -- Treatment | Amyloid beta-protein | Alzheimer Disease -- drug therapy | Alzheimer Disease -- physiopathology | Alzheimer Disease -- therapy | Amyloid beta-Peptides -- toxicityOnline resources: Click here to access online | Series (Alzheimer disease) | Series (Drug discovery and development in the neurosciences) Animated audio-visual presentation with synchronized narration.
Title from publisher's website (viewed January 2012).
Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. PBT2 -- Alzheimer's disease Abeta-directed therapeutics in clinical development: drugs and biologics -- Phase II results of Abeta targeting AD modifying drugs.
Access restricted to subscribers.
Mode of access: World Wide Web.